drugset
drugset / Trial / NCT05166031

Evaluation of the Immunogenicity and Safety of Concomitant Administration of Novel Oral Polio Type 2 Vaccine and Bivalent Oral Polio Vaccine

NCT05166031 ↗

Phase 3 Withdrawn Fidec Corporation Bill and Melinda Gates Foundation · collab
RandomizedParallel-groupDouble-blindPrevention

Summary

The study will assess and compare the immune response and safety following the co-administration of Novel Oral Polio Type 2 (nOPV2) and bivalent Oral Polio Vaccine (bOPV) in comparison with nOPV2 or bOPV in infants aged 2 months who have never received vaccination against poliomyelitis.

Timeline

Start
2020-12
Primary completion
2021-04
Completion
2021-10-18

Outcome

Outcome not reported

Stopped: “Sponsor decided not to conduct it”

Drugs

EvaluationDrugModalityDoseRoute
Subject bivalent Oral Polio Vaccine Vaccine — Oral
Subject nOPV2 Vaccine — Oral

Indications

poliomyelitis